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Abstract
Background: Yellow fever (YF) virtually disappeared in francophone West African countries as a result of YF mass
vaccination campaigns carried out between 1940 and 1953. However, because of the failure to continue mass vaccination
campaigns, a resurgence of the deadly disease in many African countries began in the early 1980s. We developed an original
modeling approach to assess YF epidemic risk (vulnerability) and to prioritize the populations to be vaccinated.
Methods and Findings: We chose a two-step assessment of vulnerability at district level consisting of a quantitative and
qualitative assessment per country. Quantitative assessment starts with data collection on six risk factors: five risk factors
associated with ‘‘exposure’’ to virus/vector and one with ‘‘susceptibility’’ of a district to YF epidemics. The multiple
correspondence analysis (MCA) modeling method was specifically adapted to reduce the five exposure variables to one
aggregated exposure indicator. Health districts were then projected onto a two-dimensional graph to define different levels
of vulnerability. Districts are presented on risk maps for qualitative analysis in consensus groups, allowing the addition of
factors, such as population migrations or vector density, that could not be included in MCA. The example of rural districts in
Burkina Faso show five distinct clusters of risk profiles. Based on this assessment, 32 of 55 districts comprising over 7 million
people were prioritized for preventive vaccination campaigns.
Conclusion: This assessment of yellow fever epidemic risk at the district level includes MCA modeling and consensus group
modification. MCA provides a standardized way to reduce complexity. It supports an informed public health decision-
making process that empowers local stakeholders through the consensus group. This original approach can be applied to
any disease with documented risk factors.
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Introduction
After several decades of relative calm, yellow fever (YF) outbreaks
have had a resurgence in Africa, posing an immediate risk to the
affected populations across the continent. Increasing migration,
accelerating urbanization, and improved travel infrastructure are
global trends that increase the risk of YF spreading to parts of the
world where the disease has disappeared, such as Europe or North
America, or never seen before, such as Asia [1–14]. Because of the
risk of international spread, YF is one of the diseases officially
reported under the International Health Regulations. The contin-
ued use of the YF vaccination certificate is a tangible sign of the
constant threat posed by the disease at a global level [15–20].
The most effective measure for preventing and controlling YF
outbreaks is vaccination. The development of a YF vaccine in the
1930s was a turning point in the history of the disease, because a
single dose of the vaccine that is considered safe and effective is
sufficient to protect an individual for at least 10 years and probably
up to 35 years [21–24]. Between 1933 and 1961, mass vaccination
campaigns were carried out in several francophone West African
countries, resulting in the rapid disappearance of the disease over
the subsequent 40 years [25–27]. The mass vaccination campaigns
stopped in the 1960s when the French neurotropic vaccine (FNV)
stopped being recommended for children under 10 years old
because of the noted association with a high incidence of
encephalitis reaction in this age group [28,29]. The production
of FNV stopped in 1980. Today the 17D vaccine is the only type
of YF vaccine produced and used for vaccination.
While anglophone countries such as Nigeria experienced
devastating YF outbreaks in the 1980s, francophone countries
reported limited YF outbreaks. These outbreaks mainly appeared
in nomadic communities or among seasonal workers (e.g., in
Senegal 1965 and Burkina Faso 1983) who did not benefit from
previous mass vaccination campaigns [30–34].
www.plosntds.org 1 July 2009 | Volume 3 | Issue 7 | e483Since 2000, a number of YF outbreaks have been reported in
West African countries, especially in capitals and large cities [35–
40] such as Abidjan, Ivory Coast (2001); Dakar, Senegal (2002);
Touba, Senegal (2002); Conakry, Guinea (2002); and Bobo
Dioulasso, Burkina Faso (2004). The outbreaks were rapidly
controlled by emergency reactive vaccination campaigns, and the
number of YF cases has remained low.
The resurgence of this disease is related to a high proportion of
non-protected individuals in exposed communities. The YF
vaccine has been introduced into routine infant immunization
programs in 19 of the 23 (83%) high-risk African countries
endemic for YF [41]. However, with routine immunization of
children alone, it takes several decades to reduce significantly the
proportion of non-immune people in the population and thus the
risk of outbreaks. Four strategies proposed by WHO–UNICEF
have the potential to bring YF under control in Africa: (i) Rapid
response to outbreaks, (ii) routine childhood immunization, (iii)
mass preventive campaigns, and (iv) improved surveillance.
Unfortunately, in most of the YF endemic countries, coverage
for routine YF immunization is low (below 60%) and preventive
campaigns have not been carried out programmatically. The
limited implementation of recommended control strategies is due
to many factors, including competing public health priorities such
as meningitis or cholera outbreaks, the cost of the vaccination
campaigns, and limited availability of affordable YF vaccine on the
global market. The resurgence of YF is also linked to the
interaction of various environmental, economic, social, and
political factors. All these factors and their interactions make YF
epidemic risk analysis a complex and difficult process: it requires
an assessment of multiple criteria [42].
In the face of the resurgence of YF, the Global Alliance for
Vaccine and Immunization (GAVI) has funded a joint WHO–
UNICEF proposal in December 2005 to reduce YF epidemic risk
in the following 12 high-risk countries in Africa: Benin, Burkina
Faso, Cameroon, Co ˆte d’Ivoire, Ghana, Guinea, Liberia, Mali,
Nigeria, Senegal, Sierra Leone, and Togo. This initiative of
US$62 million is aimed at providing sufficient funds by 2010 for
the immunization of 48 million people, which represents
approximately 17% of the population of the 12 targeted countries.
In order to best use this limited international funding it is
important to define levels of risk for YF outbreaks and to target
high-risk communities for priority vaccination.
This article describes the process, methodology, and tools used
to identify high-risk populations for priority vaccination, and the
multiple correspondence analysis (MCA) and consensus assess-
ment at the country level used as decision-making tools.
Methods
Overall risk assessment structure
The frame of reference chosen to identify communities at
highest risk is derived from the model of Sutherts to assess the
vulnerability of the population to vector-borne diseases. The
vulnerability may be defined as the economic, social, or political
predisposition of a community to destabilization by an external,
natural, or man-made phenomenon [43]. YF vulnerability
depends on three parameters: susceptibility of the community to
infection, exposure to the YF virus, and resilience of the
population at risk [26,44].
Vulnerability~Susceptibility|Exposure| 1{Resilience ðÞ
The susceptibility to or likelihood of a community being affected
by a YF outbreak depends on population immunity, which is
mainly related to the proportion of vaccinated people in a
community. Susceptibility usually varies among countries and
districts. Since the reemergence of YF in Africa, affected countries
have embarked on preventive immunization campaigns or
epidemic response campaigns, and have incorporated YF vaccine
into the routine infant immunization schedule. Evidence suggests
that epidemic risk in a community diminishes considerably once
60%–80% of the population in that community has been
immunized [45–47]. Since mass vaccination campaigns may not
reach 100% of the population, sporadic cases in a vaccinated
population can still occur, but transmissions rate will remain low
and will not amplify into epidemic transmission. Sporadic cases
are also seen in non-immunized migrants settling in areas with
infected mosquitoes.
The exposure is defined by the likelihood for a community to be
in contact with the YF virus through infected Aedes mosquitoes.
Resilience is the ability to control and recover quickly from an
outbreak, and it depends on the capacity to quickly detect
outbreaks and rapidly launch mass vaccination campaigns.
Development of the risk assessment tool
The final product was a district-level assessment of vulnerability
within countries. The assessment was derived from two processes,
one quantitative and one qualitative. The quantitative assessment
was based on the selection of key variables followed by a formal
MCA [48–54]. This process led to a graphic representation of
districts’ vulnerability profile, allowing the definition of vaccination
priorities according to the profile of vulnerability. The qualitative
process consisted of consensus expert groups meeting at the
country level that reviewed the results from the quantitative
assessment and adjusted the districts’ classifications based on
additional information available at the country level. These groups
consisted of various experts in the fields of epidemiology, virology,
entomology, and public health from Ministries of Health, WHO,
UNICEF, Institut Pasteur, and international nongovernmental
organizations (NGOs).
Author Summary
This article describes the use of an original modeling
approach to assess the risk of yellow fever (YF) epidemics.
YF is a viral hemorrhagic fever responsible in past centuries
for devastating outbreaks. Since the 1930s, a vaccine has
been available that protects the individual for at least 10
years, if not for life. However, immunization of populations
in African countries was gradually discontinued after the
1960s. With the decrease in immunity against YF in African
populations the disease reemerged in the 1980s. In 2005,
WHO, UNICEF, and the GAVI Alliance decided to support
preventive vaccination of at-risk populations in West
African endemic countries in order to tackle the reemer-
gence of YF and reduce the risk of urban YF outbreaks.
Financial resources were made available to scale up a
global YF vaccine stockpile and to support countries with
limited resources in the management of preventive
vaccination campaigns. This article describes the process
we used to determine the most at-risk populations using a
mathematical model to prioritize targeted immunization
campaigns. We believe that this approach could be useful
for other diseases for which decision making process is
difficult because of limited data availability, complex risk
variables, and a need for rapid decisions and implemen-
tation.
Assessment of Yellow Fever Epidemic Risk
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Selection of variables. YF risk factors fall into three main
categories: human, mosquito, and animal host, additionally
influenced by the climate and ecological environment. The
selection of relevant factors and related variables was done by an
international expert panel. It was based on two sets of criteria (i) the
relevance to the objective of the assessment, which is to identify
populations to be vaccinated in priority; and (ii) availability and
quality of data in all counties included in the initiative. We sought to
identify factors based on data availability—which varies
considerably across the 12 identified African countries—to
facilitate the comparability of data between populations. Given
the urgency of providing information to guide vaccination
campaigns, we considered only currently existing data or data that
could be easily collected without carrying out additional surveys.
This approach was pilot tested in Burkina Faso to determine the
feasibility and accuracy of the risk assessment tool before it was used
in the remaining 11 countries targeted by the YF initiative. All data
were gathered at the health district level in collaboration with the
Ministries of Health and the WHO country office.
The expert panel selected six indicators that were collected in
the pilot country. Five ‘‘exposure-related’’ indicators were
identified:
1. District situated in the ecological risk zone 15uN–10uS, wet
savannah or dry forest [22]: Yes/No response (see Figure 1)
2. District reporting confirmed cases since 1960: Yes/No
response (see Figure 2)
3. District reporting suspected cases between 1960 and the
establishment of surveillance based on laboratory-confirmed
cases: Yes/No response
4. Number of years in which any YF cases were reported since
1960 in this district
5. District close to another district that had any reported cases
since 1960: Yes/No response
Modeling with multiple correspondence analysis (described in
more detail below) was used to reduce the five exposure variables
into a single aggregated exposure indicator.
Thesecond indicatorwasa ‘‘communitysusceptibility’’indicator,
which represents the proportion of non-immunized persons in the
district. This information was obtained by subtracting the number
of persons already immunized from the total health district
population. The number of vaccinated persons consisted of all
vaccinated children and adults, vaccinated through either preven-
tive or epidemic response campaigns, plus the number of infants
immunized under the routine immunization program for the last 10
Figure 1. District situated in the ecological risk zone 15uN–10uS, wet savannah or dry forest (Source: FAO).
doi:10.1371/journal.pntd.0000483.g001
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administrative vaccination coverage data.
Indicators related to resilience were too numerous and various
in countries for inclusion in the quantitative process. This
important part of the analysis was therefore kept for the qualitative
assessment. The quantitative assessment of vulnerability thus was
defined by the aggregated exposure indicator and the susceptibility
indicator.
Multiple correspondence analysis. MCA is a descriptive
technique developed in the 1970s by Jean-Paul Benze ´cri [48].
Although mostly used in socio-economic research it allows the
analysis of any kind of complex matrix [51,54]. MCA belongs to a
group of multiple-criteria analysis techniques including a range of
similar modeling techniques, such as factor analysis, cluster
analysis, segmentation analysis, and neuronal network modeling
[49,55–57]. MCA was selected for the YF risk assessment for the
following reasons: it is reproducible, results are understandable by
national health authorities, it can address quantitative and
qualitative variables, and it has the potential to generate a
‘‘quality indicator’’ to assess the robustness of the outcome.
For the current risk assessment, the five exposure variables were
placed in columns and health districts in rows. MCA was used to
‘‘aggregate’’ the various exposure variables into a single aggregated
exposure indicator. Usually MCA is used to project initial variables
in a ‘‘factorial graph’’composed on twoaxes. In this riskassessment,
we have programmeda specificMCA,which allowed the projection
of the five exposure variables into one single axis (exposure axis).
The interpretation of the factorial graph is much easier than the
interpretation of the matrix, namely: the closer the districts lie
together in the factorial graph, the more similar they are in terms
of level of exposure.
Many professional statistical software tools include standard
MCAs. However, no marketed package allows selection of the axis
that would best synthesize risk factors and projection of multi-
dimensional data on this single axis. This is the reason we have
specifically programmed for this project a MCA tool that can
manage large matrix calculations and allows the construction and
the interpretation of one single-dimension factorial graph.
A vulnerability graph was built assigning the susceptibility
variable to the y-axis and the aggregated exposure indictor to the
x-axis (see Figure 3). The vulnerability profile of each district
depends on its position on the graph, defined by the susceptibility
value and the exposure value
Four profiles were defined on this graph based on the
susceptibility and exposure threshold. The susceptibility threshold
was set at 40%, indicating that .60% of the population has been
immunized and that the risk of an epidemic is lower [46,58]. The
exposure threshold was discussed during the consensus meeting and
is specific to each country. There is no absolute threshold value for
exposure, because the value of the aggregated exposure indicator
was relative to the group of districts considered in the analysis.
As noted above, the quantitative assessment profiles four clusters
of districts characterized as follows (see Figure 4):
Profile 1: High exposure+high susceptibility: Very
vulnerable, high priority for vaccination.
Profile 2: High exposure+low susceptibility: Vulnerable
but no preventive vaccination in coming years because
Figure 2. Yellow fever cases reported in Burkina Faso from 1950 to 2004.
doi:10.1371/journal.pntd.0000483.g002
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years.
Profile 3: Low exposure+high susceptibility: Vulnerable
but lower risk than districts in profile 1.
Profile 4: Low exposure+low susceptibility: Low vulner-
ability and lower priority than districts in profile 2.
The analysis was done separately for urban and rural districts to
better reflect the current urbanization of the YF risk and to
account for population density as an important parameter for the
whole risk analysis.
Qualitative assessment. Following the assignment of
district vulnerability based on the above quantitative process, we
convened consensus groups to evaluate the results and modify
them if necessary, with particular emphasis on identifying
additional districts at high risk that were not identified through
the quantitative assessment. Consensus group members included
staff members of the Ministries of Health, members of
nongovernmental organizations with vaccination activities, and
international or national YF experts. Consensus groups were
instructed to modify the results of the quantitative process to
reflect additional local data not included in the quantitative
process. These elements included factors such as population
migration, main roads linked to districts at risk, resilience of the
district, nomadic communities crossing the district, living
conditions, and other evidence-based factors that could have an
impact on the vulnerability to YF as defined in the vulnerability
framework.
Figure 3. Yellow fever vulnerability model for decision making.
doi:10.1371/journal.pntd.0000483.g003
Figure 4. Yellow fever vulnerability profiles of districts
identified with the quantitative assessment.
doi:10.1371/journal.pntd.0000483.g004
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The vulnerability graph obtained for rural districts in Burkina
Faso illustrates the results of the quantitative analysis (Figure 5).
The rural districts were clustered into five distinct groups. The
two clusters of districts on the right of the graph were judged to be
very vulnerable (Profile 1, see Methods for definition). Therefore,
the threshold for exposure was defined by consensus to be placed
at point 0.4 of the exposure axis.
The qualitative process identified additional clusters for
inclusion in Profile 1. The district of Yako, although in quadrant
III (Profile 3 in Figure 4), was considered to be very vulnerable
because of its market-gardening industry and the significant cross-
border migration occasioned by this commercial activity. Both
characteristics, which were not considered in the exposure
variable, were included in the MCA model.
The same analysis was performed separately for urban districts.
A map of the vulnerability of rural and urban districts in Burkina
Faso is presented (Figure 6). The capital city of Ouagadougou as
well as Tenkodogo, Koudougou, and Fada were classified as
Profile 1 and will be prioritized for vaccination in the next
preventive campaign, whereas the cities of Bobodioulasso,
Dedougou, and Banfora were in Profile 2. They have already
been vaccinated and they do not need to be revaccinated in the
coming years unless the migration rate is known to be high enough
to renew the population in a few years time. The other cities,
Kaya, Ouhigouya, and Dori, were not priorities for preventive
campaigns in the coming years.
On the basis of this analysis a vaccine prioritization schedule
was developed including 32 districts out of 55 (see Figure 6)
representing 7.8 million people at highest priority for an
immediate preventive campaign.
Discussion
In this article we present the process, which included MCA
and consensus group modification, of defining priority commu-
nities that would benefit from a YF preventive immunization
campaign.
This process starts from a small set of quantitative elements that
identify most districts at risk but also engages local decision
makers to complement and interpret the results. The MCA
allowed the representation of a complex multidimensional
situation into a two-dimensional graph that visualizes the
communities at highest risk in a concise and reader-friendly
way. MCA provides a standardized way to reduce complexity to
support an informed decision-making process and allocate
effectively the limited resources that are available for this
preventive intervention.
The risk assessment is based on the combination of the
standardized analysis of defined factors through MCA and
information gathered during the consensus meeting that draws
on a range of data sources such as epidemic investigation reports,
routine surveillance data, or interviews with key personnel in the
risk management system. Countries are involved at different steps
in the process. The data matrix used for the modeling was verified
by the Ministry of Health of Burkina Faso. During the consensus
meeting local stakeholders provided information on important risk
factors that cannot be handled by the model, for example
migratory flows, nomadic populations, and resilience in a
Figure 5. Yellow fever vulnerability of rural districts in Burkina Faso.
doi:10.1371/journal.pntd.0000483.g005
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the modelers and local stakeholders also provided a better
assimilation of the results by the nationals. The full endorsement
by the country of the result of the modeling is critical, as the final
result of the RA will be translated into the practical implemen-
tation of vaccination campaigns, which requires national funding
in addition to international financial support. This approach for
risk assessment not only supports evidence-based decision making
but also empowers decision makers in countries receiving
international support for YF control. A criterion for validity of
such a process could be the catalytic authenticity which is the
extent to which action is stimulated and facilitated by the risk
assessment process [59].
One limitation of the described process is that factor analysis
such as MCA requires a good dataset with no missing data. The
nature of the dataset influences the selection of variables, as
mentioned before, and requires control of the quality of the data
input into the matrix. The limited amount of information over a
long period of time for some indicators was a constraint for
integrating more variables into the model. Moreover, the lack of
data for some variables, initially considered important during the
expert panel meeting, did not allow their final integration into the
model. However, the addition of the qualitative consensus review
allowed us to overcome this limitation in an efficient manner. The
exposure analysis we obtained is similar to the results from other
risk mapping studies [14]. The result of the pilot study in Burkina
Faso showed that the risk assessment reflects what was instinctively
assumed by local health experts. This evidence-based confirmation
of subjective knowledge was an important step in the buy-in of
political decision makers and the planning of the vaccination
campaigns. To date, the risk assessment approach has been used in
another seven countries, and results have confirmed the pragmatic
approach of this decision-making tool.
A second limitation of the risk assessment tool is the relative (not
absolute) characteristics of the aggregated exposure indicator. This
limitation means that this value must be compared and interpreted
in the frame of one given country and cannot be compared with
values calculated from other analyses. If the aggregated exposure
indicator equals 1.2 for a district in Burkina Faso, it does not mean
that a Togolese district with the same value has the same exposure.
This is not a major constraint, as the objective of the YF risk
assessment is to rank districts primarily for facilitation of national-
level decision-making processes.
The main advantage of multiple correspondence analysis is
that the model analyses data without altering the parameters
beforehand through scoring procedures and weighting systems.
Variables are not weighted before being introduced into the
model, but MCA itself, through the comparison of the data of
each district, defines the reciprocity of variables for each model
outcome. Allowing MCA to define which variables best describe
the risk situation for each analysis ensures the highest attainable
degree of objectivity. Scoring procedures have often been used
for risk assessment using the additive function, with or without
weights. Unfortunately, the scoring technique (additive or
Figure 6. Vulnerability map of all districts in Burkina Faso.
doi:10.1371/journal.pntd.0000483.g006
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profiles. For instance, for the YF risk assessment, different
values for the five exposure indicators could lead to a similar
exposure score. Furthermore, additive scoring procedures often
imply managing qualitative variables with subjective assump-
tions.
This experience shows the robustness of MCA when used
with a limited number of variables. It also highlights the
potential use of such a methodology for supporting an evidence-
based public-health decision-making process in countries where
surveillance data of good quality are scarce. A similar
methodology based on an original, robust, and reproducible
technique—able to give a simple representation of a complex
reality—could be used for other infectious diseases such as avian
influenza when multiple risk factors at the animal–human
interface are interconnected.
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